Table 3. Multivariate Analysis of Factors Associated With Progression-Free Survival^a.

Risk factor	Effect	HR (95% CI)	P value
Baseline LDH level	Elevated vs normal	1.45 (1.27-1.65)	<.001
ECOG PS at screening	1 vs 0	1.20 (1.06-1.36)	.004
Ipilimumab exposureb	Ipilimumab exposed vs ipilimumab naive	1.13 (1.00-1.28)	.042
PD-L1 status	Negative vs positive	1.58 (1.35-1.84)	<.001
Baseline tumor size	>93 mm vs ≤93 mmc	1.44 (1.26-1.65)	<.001
Prior systemic BRAFi therapy	Yes vs no	1.31 (1.14-1.52)	<.001
Sex	Female vs male	1.23 (1.09-1.38)	<.001
Albumin	≤0.834 vs >0.834	1.23 (1.08-1.40)	<.001

Abbreviations: BRAFi, BRAF inhibitor; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; LDH, lactate dehydrogenase; PD-L1, programmed death ligand 1.

^aAnalysis included all patients, regardless of BRAF mutation status. Progression-free survival was determined by Response Evaluation Criteria in Solid Tumors, version 1.1, per investigator review.

^bThe clinical study and prior ipilimumab exposure were highly correlated, and only 1 could be included in the model. See eTable 3 in the Supplement for multivariate analysis with study included as a covariate instead of ipilimumab exposure.

^cCutoff chosen based on the value that showed the most significant difference in response.